The preparation of monoclonal immunoglobulin loaded dendritic cells vaccine for myeloma patients under GMP conditions: preclinical and first clinical results of a phase I/II clinical trial.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F07%3A00019217" target="_blank" >RIV/00216224:14110/07:00019217 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The preparation of monoclonal immunoglobulin loaded dendritic cells vaccine for myeloma patients under GMP conditions: preclinical and first clinical results of a phase I/II clinical trial.

Popis výsledku v původním jazyce

Feasibility and safety of vaccination with Id-protein loaded autologous dendritic cells was proved in patients with multiple myeloma under the GMP conditions. Adjuvant immunotherapy with antigen-loaded dendritic cells (DCs) represents a novel and relatively non-toxic treatment modality for multiple myeloma (MM). Malignant cells in MM produce a monoclonal immunoglobulin (idiotypic protein) which is considered a tumor-specific antigen and can be used for the induction of T lymphocytes. To enhance the anti-myeloma immune response, the idiotypic protein (Id-protein) can be loaded into autologous DCs and used for vaccination. Aims: The aim of this study was to evaluate DC-based vaccine preclinically and test the safety and the immune response of the vaccinein patients with MM. Patients and Methods: Pre-clinical testing was performed in 8 patients with MM. DC loaded with autologous myeloma cells were used for autologous T cell stimulation in vitro.

Název v anglickém jazyce

The preparation of monoclonal immunoglobulin loaded dendritic cells vaccine for myeloma patients under GMP conditions: preclinical and first clinical results of a phase I/II clinical trial.

Popis výsledku anglicky

Feasibility and safety of vaccination with Id-protein loaded autologous dendritic cells was proved in patients with multiple myeloma under the GMP conditions. Adjuvant immunotherapy with antigen-loaded dendritic cells (DCs) represents a novel and relatively non-toxic treatment modality for multiple myeloma (MM). Malignant cells in MM produce a monoclonal immunoglobulin (idiotypic protein) which is considered a tumor-specific antigen and can be used for the induction of T lymphocytes. To enhance the anti-myeloma immune response, the idiotypic protein (Id-protein) can be loaded into autologous DCs and used for vaccination. Aims: The aim of this study was to evaluate DC-based vaccine preclinically and test the safety and the immune response of the vaccinein patients with MM. Patients and Methods: Pre-clinical testing was performed in 8 patients with MM. DC loaded with autologous myeloma cells were used for autologous T cell stimulation in vitro.

Druh

O - Ostatní výsledky

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8945" target="_blank" >NR8945: Buněčná imunoterapie s využitím různých nádorových antigenů u mnohočetného myelomu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů